The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: Encouraging results from a prospective study

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 111-117

  Frechette, Dominique ^a   Paquet, Lise ^b   Verma, Shailendra ^c   Clemons, Mark ^c   Wheatley Price, Paul ^c   Gertler, Stan Z ^c   Song, Xinni ^c   Graham, Nadine ^d   Dent, Susan ^c  

^a Centre de Santé et Services Sociaux de Gatineau   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Endocrine symptoms; Endocrine therapy; Sexual distress; Sexual dysfunction

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVOR; CONTROLLED STUDY; DISTRESS SYNDROME; EARLY CANCER; FEMALE; FEMALE SEXUAL DISTRESS SCALE; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SEXUAL AROUSAL DISORDER; SEXUAL FUNCTION; SEXUAL SATISFACTION; TREATMENT DURATION; VAGINAL LUBRICATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CERVIX MUCUS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DYSPAREUNIA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIBIDO; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PREVALENCE; PROGESTERONE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TAMOXIFEN;

EID: 84884282830     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2659-y     Document Type: Article

References (50)

1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical Oncology (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784-3796
2. National Comprehensive Cancer Network (2010) National Comprehensive Cancer Network: Clinical practice guidelines in breast cancer, version1 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
3. Fallowfield L (2011) Identification and management of treatment-related symptoms for breast cancer patients receiving adjuvant endocrine therapy. Eur J Cancer 47(Suppl 1):S80-S80
4. Bradford A (2013) Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 20(2):128-129
5. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol 31(11):1398-1404
6. Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Siggelkow W, Kandelhardt E, Koelbl H (2009) Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care (Engl) 18(5):500-506
7. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936-942
8. Mok K, Juraskova I, Friedlander M (2008) The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. Breast 17(5):436-440
9. Dent SF, Gaspo R, Kissner M, Pritchard KI (2011) Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 126(2):295-310
10. Buijs C, de Vries EG, Mourits MJ, Willemse PH (2008) The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev 34(7):640-655
11. Chin SN, Trinkaus M, Simmons C, Flynn C, Dranitsaris G, Bolivar R, Clemons M (2009) Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 9(2):108-117
12. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97(5 Pt 2):855-866
13. Berglund G, Nystedt M, Bolund C, Sjödén PO, Rutquist LE (2001) Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 19(11):2788-2796
14. Fobair P, Stewart SL, Chang S, D'Onofrio C, Banks PJ, Bloom JR (2006) Body image and sexual problems in young women with breast cancer. Psychooncology 15(7):579-594
15. Safarinejad MR, Shafiei N, Safarinejad S (2012) Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology 22(6):1242-1248
16. Ochsenkühn R, Hermelink K, Clayton AH, von Schönfeldt V, Gallwas J, Ditsch N, Rogenhofer N, Kahlert S (2011) Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder. J Sex Med 8(5):1486-1494
17. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J (2008) Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? J Sex Med 5(8):1898-1906
18. Biglia N, Moggio G, Peano E, Sgandurra P, Ponzone R, Nappi RE, Sismondi P (2010) Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 7(5):1891-1900
19. Gilbert E, Ussher JM, Perz J (2010) Sexuality after breast cancer: a review. Maturitas 66(4):397-407
20. Melisko ME, Goldman M, Rugo HS (2010) Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv 4(3):247-255
21. Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA (2005) Study of sexual functioning determinants in breast cancer survivors. Breast J 11(6):440-447
22. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (1999) Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17(5):1488-1492
23. Mourits MJ, Böckermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH (2002) Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86(10):1546-1550
24. Panjari M, Bell RJ, Davis SR (2011) Sexual function after breast cancer. J Sex Med 8(1):294-302
25. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162-168
26. Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96(5):376-387
27. Greendale GA, Petersen L, Zibecchi L, Ganz PA (2001) Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 8(2):111-119
28. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E, Leiblum S, Padma-Nathan H, Rosen R, Segrayes K, Segrayes RT, Shabsigh R, Sipski M, Wagner G, Whipple B (2000) Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 163:888-893
29. Mimoun S, Wylie K (2009) Female sexual dysfunctions: definitions and classification. Maturitas 63(2):116-118
30. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB (2008) Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 112(5):970-978
31. Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU (2009) Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry 70(12):1698-1706
32. Smith AM, Lyons A, Ferris JA, Richters J, Pitts MK, Shelley JM, Simpson JM, Heywood W, Patrick K (2012) Incidence and persistence/recurrence of women's sexual difficulties: findings from the Australian longitudinal study of health and relationships. J Sex Marital Ther 38(4):378-393
33. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the Fact-B. Breast Cancer Res Treat 55(2):189-199
34. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974-986
35. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y (2008) Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 5(2):357-364
36. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr (2002) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191-208
37. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y (2008) Validation of the female sexual distress scale - revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 5(2):357-364
38. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 28(4):317-330
39. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd edn. Wiley, New York
40. Mercadante S, Vitrano V, Catania V (2010) Sexual issues in early and late stage cancer: a review. Support Care Cancer 18(6):659-665
41. Gilbert E, Ussher JM, Perz J (2010) Sexuality after breast cancer: a review. Maturitas 66(4):397-407
42. Bradford A (2013) Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 20(2):128-129
43. Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J (2010) Clinical factors are not the best predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. Psychooncology 19(6):646-656
44. Harirchi I, Montazeri A, Zamani Bidokhti F, Mamishi N, Zendehdel K (2012) Sexual function in breast cancer patients: a prospective study from Iran. J Exp Clin Cancer Res 31:20
45. Pérez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924-937
46. Kingsberg SA (2010) Sexual problems in breast cancer survivors: do not turn good news into no news. Menopause 17(5):894-895
47. Katz A (2005) The sounds of silence: sexuality information for cancer patients. J Clin Oncol 23(1):238-241
48. Park ER, Norris RL, Bober SL (2009) Sexual health communication during cancer care: barriers and recommendations. Cancer J 15(1):74-77
49. Brandenburg U, Bitzer J (2009) The challenge of talking about sex: the importance of patient-physician interaction. Maturitas 63(2):124-127
50. Bober SL, Carter J, Falk S (2013) Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 10(Suppl 1):112-119